Directors of the California stem cell agency this morning put off major proposed changes in the review process for high profile grant applications in clinical trial and disease team rounds.
Director Jeff Sheehy, chair of the directors' Science Subcommittee, sought the delay because, saying that the leadership of the committee and CIRM staff had not been able to reach a consensus on the language. There was no discussion on the matter.
Earlier this month, CIRM staff indicated some urgency existed concerning implementation of the plan.
No comments:
Post a Comment